These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31652356)

  • 1. The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening.
    Berger VK; Norton ME; Sparks TN; Flessel M; Baer RJ; Currier RJ
    Prenat Diagn; 2020 Jan; 40(2):185-190. PubMed ID: 31652356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive predictive value estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory.
    Petersen AK; Cheung SW; Smith JL; Bi W; Ward PA; Peacock S; Braxton A; Van Den Veyver IB; Breman AM
    Am J Obstet Gynecol; 2017 Dec; 217(6):691.e1-691.e6. PubMed ID: 29032050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing on screening policies and prenatal ultrasound practice.
    Salomon LJ; Alfirevic Z; Audibert F; Kagan KO; Paladini D; Yeo G; Raine-Fenning N;
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):815-816. PubMed ID: 28573775
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical Review of Noninvasive Prenatal Testing: Experience from 551 Pregnancies with Noninvasive Prenatal Testing-Positive Results in a Tertiary Referral Center.
    Wu X; Li Y; Xie X; Su L; Cai M; Lin N; Du S; Xu L; Huang H
    J Mol Diagn; 2020 Dec; 22(12):1469-1475. PubMed ID: 33069877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal diagnosis of fetuses with increased nuchal translucency using an approach based on quantitative fluorescent polymerase chain reaction and genomic microarray.
    Pan M; Han J; Zhen L; Yang X; Li R; Liao C; Li DZ
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():164-7. PubMed ID: 26771907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine first-trimester screening for fetal trisomies in twin pregnancy: cell-free DNA test contingent on results from combined test.
    Galeva S; Konstantinidou L; Gil MM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Feb; 53(2):208-213. PubMed ID: 30353581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?
    Bardi F; Bosschieter P; Verheij J; Go A; Haak M; Bekker M; Sikkel E; Coumans A; Pajkrt E; Bilardo C
    Prenat Diagn; 2020 Jan; 40(2):197-205. PubMed ID: 31697852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Validation of Non-Invasive Prenatal Testing for Fetal Common Aneuploidies in 1,055 Korean Pregnant Women: a Single Center Experience.
    Lee DE; Kim H; Park J; Yun T; Park DY; Kim M; Ryu HM
    J Korean Med Sci; 2019 Jun; 34(24):e172. PubMed ID: 31222985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of a contingent screening strategy for trisomies with cell-free DNA: a pilot study.
    Sánchez-Durán MÁ; Bernabeu García A; Calero I; Ramis Fossas J; Illescas T; Avilés MT; Maiz N; Carreras E
    BMC Pregnancy Childbirth; 2019 Aug; 19(1):274. PubMed ID: 31370808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive prenatal testing for aneuploidy screening.
    Spencer R; Hewitt H; McCarthy L; Wimalasundera R; Pandya P
    BMJ; 2020 Oct; 371():m3930. PubMed ID: 33109517
    [No Abstract]   [Full Text] [Related]  

  • 13. Reexamining the optimal nuchal translucency cutoff for diagnostic testing in the cell-free DNA and microarray era: results from the Victorian Perinatal Record Linkage study.
    Hui L; Pynaker C; Bonacquisto L; Lindquist A; Poulton A; Kluckow E; Hutchinson B; Norris F; Pertile MD; Gugasyan L; Kulkarni A; Harraway J; Howden A; McCoy R; da Silva Costa F; Menezes M; Palma-Dias R; Nisbet D; Martin N; Bethune M; Poulakis Z; Halliday J
    Am J Obstet Gynecol; 2021 Nov; 225(5):527.e1-527.e12. PubMed ID: 33957116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment and Clinical Utility of a Non-Next-Generation Sequencing-Based Non-Invasive Prenatal Testing Technology.
    Gormus U; Chaubey A; Shenoy S; Wong YW; Chan LY; Choo BP; Oraha L; Gousseva A; Persson F; Prensky L; Chin E; Hegde M
    Curr Issues Mol Biol; 2021 Aug; 43(2):958-964. PubMed ID: 34449543
    [No Abstract]   [Full Text] [Related]  

  • 15. An efficient method for noninvasive prenatal diagnosis of fetal trisomy 13, trisomy 18, and trisomy 21.
    Sun X; Lu J; Ma X
    PLoS One; 2019; 14(4):e0215368. PubMed ID: 30978256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of increased nuchal translucency in the era of noninvasive prenatal testing with cell-free DNA.
    Holzer I; Husslein PW; Bettelheim D; Scheidl J; Kiss H; Farr A
    Int J Gynaecol Obstet; 2019 Jun; 145(3):319-323. PubMed ID: 30901484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive prenatal testing for chromosome aneuploidies and subchromosomal microdeletions/microduplications in a cohort of 8141 single pregnancies.
    Hu H; Wang L; Wu J; Zhou P; Fu J; Sun J; Cai W; Liu H; Yang Y
    Hum Genomics; 2019 Mar; 13(1):14. PubMed ID: 30871627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-free DNA screening for aneuploidies in 7113 pregnancies: single Italian centre study.
    Mesoraca A; Margiotti K; Dello Russo C; Cesta A; Cima A; Longo SA; Barone MA; Viola A; Sparacino D; Giorlandino C
    Genet Res (Camb); 2020 Jun; 102():e5. PubMed ID: 32539871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved diagnostic accuracy by using secondary ultrasound markers in the first-trimester screening for trisomies 21, 18 and 13 and Turner syndrome.
    Karadzov-Orlic N; Egic A; Milovanovic Z; Marinkovic M; Damnjanovic-Pazin B; Lukic R; Joksic I; Curkovic A; Mikovic Z
    Prenat Diagn; 2012 Jul; 32(7):638-43. PubMed ID: 22570267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-free fetal DNA analysis in maternal plasma as screening test for trisomies 21, 18 and 13 in twin pregnancy.
    Le Conte G; Letourneau A; Jani J; Kleinfinger P; Lohmann L; Costa JM; Benachi A
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):318-324. PubMed ID: 28833712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.